You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. TITLE: PLATFORM INDEPENDENT HUB FOR PATIENT REPORTED OUTCOMES (PRO) IN ONCOLOGY.

    SBC: DYNAMIC CLINICAL SYSTEMS, INC.            Topic: N/A

    N/A

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. VLP-Based Antibody-Inducing Vaccines for HIV-1

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Improved Vaccines for Influenza B Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affecting all age groups but with especially high rates of infection in children. Serious illness and death are consequences of influenza infection among the elderly, young children, and individuals with o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggested early on by Virchow in 1826 and proven more recently by others (e.g. Manning et al, 2007 Clin Ca Res 13:3951; review Wasiuk/Noelle et al. 2009 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cancer is projected to become the leading cause of death worldwide by 2010. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Multiple myeloma (MM) is a particularly deadly type of cancer. In 2008, 19,920 Americans were diagnosed with MM, and 10,690 died. Five-year survival rates are on ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. TCR-less Targeted T Cells Against Cancer

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This year cancer will become the leading cause of death worldwide. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Ideally, any cancer therapy should be effective (at killing cancerous cells), targeted (i.e. selective, to avoid killing healthy cells), permanent (to avoid relapse and met ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Samaritan Compounds Suppress Viral Replication and Prevent Neuronal Damage

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently up to 50% of HIV infected individuals including those taking antiretroviral therapy have mild neurocognitive disorder. Furthermore, the population living with HIV infection continues to grow and there are now over one million people living with HIV in the US and 42 million around the world. This indicates that persistent HIV associated cognitive impai ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  9. Prevention of College Student Mental Health Problems: A Web-Based ACT Program

    SBC: CONTEXTUAL CHANGE, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): There is a strong need for the development and dissemination of effective prevention programs for mental health problems with college students, who are at risk for depression, anxiety, eating disorders, substance use, and many other difficulties (American College Health Association, 2007). Despite the fact that University settings are well suited to deliver suc ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Customized Pharmaceutical Membranes for Fine Crystal Size Control

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Project Summary/Abstract The objective of this program is to build a platform technology based on developing membrane-crystallization technology to produce crystals of active pharmaceutical ingredients in which the crystal size and crystal form polymorph or pseudo-polymorph are controlled. Control of crystal size within a narrow range is an important part o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government